omalizumab asthma
Selected indexed studies
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. (J Allergy Clin Immunol, 2001) [PMID:11496232]
- Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study. (J Allergy Clin Immunol, 2024) [PMID:39186985]
- Omalizumab for Severe Asthma: Beyond Allergic Asthma. (Biomed Res Int, 2018) [PMID:30310816]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. (2001) pubmed
- Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study. (2024) pubmed
- Omalizumab for Severe Asthma: Beyond Allergic Asthma. (2018) pubmed
- Omalizumab beyond asthma. (2012) pubmed
- Omalizumab in the Therapy of Pediatric Asthma. (2018) pubmed
- Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. (2005) pubmed
- Omalizumab: not only for asthma. (2008) pubmed
- Omalizumab in the treatment of asthma. (2011) pubmed
- Pediatric use of omalizumab for allergic asthma. (2020) pubmed
- Should omalizumab be used in severe asthma/COPD overlap? (2018) pubmed